羟氯喹血药浓度监测对狼疮结局影响的真实世界纵向数据
该研究基于前瞻性SLE队列247例患者962次访视,分析体重给药下羟氯喹血药浓度的变异因素及其与疾病活动的关系。结果显示,肾小球滤过率≤75的患者在5 mg/kg/day剂量下出现超治疗浓度;血药浓度低于治疗范围与活动性SLE风险升高相关,每增加100 ng/mL与活动性SLE和复发风险降低相关。
要点
- 肾小球滤过率≤75 mL/min/1.73m2的患者在5 mg/kg/day剂量下出现超治疗浓度。
- 血药浓度<200 ng/mL和200至<750 ng/mL与活动性SLE风险升高相关。
- 血药浓度每增加100 ng/mL与活动性SLE和复发风险降低相关。
核心结论
- 羟氯喹血药浓度监测可改善SLE控制,尤其对估算肾小球滤过率≤75的患者,并有助于优化羟氯喹使用。
研究设计与样本
- 前瞻性SLE队列研究,分析247例患者共962次访视,使用广义线性混合模型和组内-组间分解模型。
主要发现
- 基线时平均年龄47岁,91%为女性,66%为白人,45%血药浓度低于治疗范围(<750 ng/mL),79%接受≤5 mg/kg/day剂量。
- 肾小球滤过率≤75 mL/min/1.73m2的患者尽管接受5 mg/kg/day,随时间出现超治疗浓度。
- 血药浓度<200 ng/mL和200至<750 ng/mL相比治疗浓度,活动性SLE的比值比分别升高6.7倍和2.6倍。
- 患者个体水平上,每次访视血药浓度增加100 ng/mL,活动性SLE和复发的比值比分别降低33%和22%。
关键数值与推荐
- 治疗性羟氯喹血药浓度范围为750-1,150 ng/mL。
- 超治疗浓度和低于治疗范围的界定依据原文治疗范围。
临床怎么用
- 对SLE患者,尤其肾小球滤过率≤75者,可考虑监测羟氯喹血药浓度以指导剂量调整。
- 维持羟氯喹血药浓度在750-1,150 ng/mL可能有助于降低活动性SLE和复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight-based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict significant variations in HCQ blood levels despite weight-based HCQ dosing, and we examined if maintaining therapeutic HCQ levels (750-1,150 ng/mL) improved SLE outcomes. METHODS: We analyzed 962 visits from 247 patients in a prospective SLE cohort. Generalized linear mixed models with random intercepts and slopes assessed associations among variables such as chronic kidney disease, HCQ dose, and HCQ blood levels over time. Next, within- and between-subject decomposition models evaluated the impact of intra- and inter-individual changes in HCQ blood levels and therapeutic HCQ blood levels on active SLE and flares over time. RESULTS: At baseline visit, the mean patient age was 47 years; 91% were female, 66% were White, 45% had subtherapeutic HCQ levels (<750 ng/mL), and 79% received an HCQ dose of ≤5 mg/kg/day. Despite receiving 5 mg/kg/day, patients with kidney function ≤75 mL/min/1.73m2 had supratherapeutic levels over time. Next, very low (<200 ng/mL) and subtherapeutic levels (200 to <750 ng/mL) predicted 6.7-fold and 2.6-fold higher odds of active SLE vs therapeutic levels over time. At the individual patient level, increases of 100 ng/mL in HCQ levels at each visit predicted 33% and 22% lower odds of active SLE and flares, respectively. CONCLUSION: HCQ blood level monitoring could improve SLE control, particularly in patients with estimated glomerular filtration rate ≤75, and enable optimal HCQ use.
引用
- Patel JJ, Hollangel F, Packee C, et al. Real-World Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study. Arthritis Care Res (Hoboken). 2026. PMID: 41983645. doi:10.1002/acr.80059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。